We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
WuXi Facility Passes FDA API Manufacture Inspection
News

WuXi Facility Passes FDA API Manufacture Inspection

WuXi Facility Passes FDA API Manufacture Inspection
News

WuXi Facility Passes FDA API Manufacture Inspection

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "WuXi Facility Passes FDA API Manufacture Inspection"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

This represents the first FDA inspection of STA’s facilities for the manufacture of an API. Last year, STA’s manufacturing operations passed an inspection by the FDA for the manufacture of an advanced intermediate. 

STA’s integrated platform of services, extending from process research to research manufacturing to commercial manufacturing, helps the company’s clients move their new chemical entities through preclinical and clinical development to global commercial launch. 

“We are very pleased to have passed a second FDA inspection of our manufacturing facilities," said Dr. Ge Li, Chairman and CEO of WuXiPharmaTech. “These favorable outcomes reflect our dedication to maintaining the highest quality standards throughout our organization.” 


Advertisement